Navigation Links
Palatin Technologies, Inc. to Report Fiscal Year 2011 First Quarter Results; Teleconference and Webcast to be Held on November 16, 2010
Date:11/12/2010

CRANBURY, N.J., Nov. 12, 2010 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) will announce its first quarter, fiscal year 2011 financial results on Tuesday, November 16, 2010 before the open of the U.S. financial markets.

Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November 16, 2010, which will include discussion of the results of operations in greater detail and an update on corporate developments.Schedule for the Financial Results Press Release, Conference Call / Webcast- Q1 Fiscal Year 2011 Financial Results Press Release

11/16/2010 at 7:30 a.m. ET- Q1 Fiscal Year 2011 Conference Call-Live

11/16/2010 at 11:00 a.m. ETDomestic Dial-In Number

1-888-215-7015International Dial-In Number

1-913-312-0376Pass code

5104164- Q1 Fiscal Year 2011 Conference Call-Replay

11/16-11/23/2010Domestic Dial-In Number

1-888-203-1112International Dial-In Number

1-719-457-0820Pass code

5104164- Webcast Live and Replay Access

http://www.palatin.comThe webcast and replay can be accessed by logging on to the "Investor/Media Center-Webcasts" section of Palatin's website at http://www.palatin.comAbout Palatin Technologies, Inc.Palatin Technologies, Inc. is a biopharmaceutical company dedicated to the development of peptide, peptide mimetic and small molecule agonists with a focus on melanocortin and natriuretic peptide receptor systems. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin Technologies' website at www.palatin.com.


'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Palatin Announces Strategic Realignment of Operations
2. Palatin Technologies, Inc. to Raise $2.0 Million Dollars in Registered Direct Offering
3. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010
4. Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate
5. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on November 16, 2009
6. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009
7. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
8. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
10. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
11. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... --  iSpecimen ®, the marketplace for human ... (DPS), a full-service anatomic pathology reference lab serving ... , has joined a program offered by iSpecimen ... to make human biospecimens and associated data available to ... in 2015 as a collaboration between iSpecimen and DHIN, ...
(Date:3/22/2017)... 22, 2017   Boston Biomedical , an industry ... to target cancer stemness pathways, today announced its Board ... as Chief Executive Officer, effective April 24, 2017. ... Li , M.D., FACP, who has led Boston Biomedical ... his leadership, Boston Biomedical has grown from a "garage ...
(Date:3/22/2017)... ... March 21, 2017 , ... Proper ... information on the desired increase and/or decrease in antibody-dependent cellular cytotoxicity or complement-dependent ... profiling of therapeutic antibodies. , To meet this demand, the team at ...
(Date:3/22/2017)... ... March 21, 2017 , ... ... innovative Quantum peristaltic pump with patented ReNu single-use (SU) cartridge technology. Engineered ... for high-pressure feed pumps in SU tangential flow filtration (TFF), virus filtration ...
Breaking Biology Technology:
(Date:3/9/2017)... MELBOURNE , Australia , March ... clinical study data at the prestigious World Lung Imaging ... Dr. Andreas Fouras , was invited to deliver ... and pulmonary medicine. This globally recognised event brings together ... and share the latest developments in lung imaging. ...
(Date:3/6/2017)... MATEO, Calif. , March 6, 2017 /PRNewswire/ ... marketing and sales technology, today announced Predictive Sales ... solution for infusing actionable sales intelligence into Salesforce. ... to automatically enable their sales organizations with deep ... messages that allow for intelligent engagement. Predictive Sales ...
(Date:3/2/2017)... -- Australian stem cell and regenerative medicine company, ... agreement with the Monash Lung Biology Network, a consortia ... Department of Pharmacology at Monash University, Melbourne ... support the use of Cymerus™ mesenchymal stem cells (MSCs) ... is a chronic, long term lung condition recognised by ...
Breaking Biology News(10 mins):